CELLAVISION AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 220.5 SEK | -3.92% |
|
-1.78% | +4.01% |
| Apr. 25 | Transcript : CellaVision AB, Q1 2024 Earnings Call, Apr 25, 2024 | |
| Apr. 25 | CellaVision AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
ETFs positioned on CellaVision AB
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 10 M€ | -3.35% | - |
CellaVision AB is a Sweden-based company active in the medical technology sector. The Company develops and sells digital solutions for medical microscopy, as well as products enabling blood cell analysis and morphology diagnosis. CellaVision ABâs product portfolio consists of analyzers for automated medical microscopy analysis and software applications designed for remote access, competency testing and education. The analyzers include such brands as CellaVision DM96 and CellaVision DM1200, whereas the software applications are divided into CellaVision Body Fluid Application, CellaVision Remote Review Software and CellaVision Competency Software, among others. The Company operates four subsidiaries, based in Sweden, Canada, the United States and Japan. In June 2014, CellaVision AB acquired technology platform from Clear Lake Medical Foundation.
Calendar
2024-05-03
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
220.5
SEK
Average target price
257.5
SEK
Spread / Average Target
+16.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.01% | 480M | |
| -12.91% | 19.08B | |
| -46.21% | 2.65B | |
| +18.15% | 1.87B | |
| -3.12% | 1.61B | |
| +23.78% | 1.21B | |
| -10.69% | 1.02B | |
| -20.89% | 905M | |
| -7.14% | 716M | |
| -18.10% | 682M |
- Stock Market
- Equities
- CEVI Stock
- Funds and ETFs CellaVision AB
